FDA Cites Ketacyn Pharmaceuticals / www.ketacynpharma.com in 2026-06-23 Warning Letter — Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
Here's the summary: The FDA's Center for Drug Evaluation and Research issued a warning letter to Ketacyn Pharmaceuticals (www.ketacynpharma.com, FEI 3043544178) on June 23, 2026, citing violations of the Federal Food, Drug, and Cosmetic Act for introducing unapproved and misbranded ketamine products into interstate commerce, including "Ketamine Solution for Injection (500 mg/10 mL)" and "Ketamine Gummies," without prior FDA approval under section 505. The agency notes that unapproved ketamine products pose serious risks including contamination, inconsistent dosing, and serious adverse events, particularly injectable formulations that bypass the body's natural defenses. The FDA requested that Ketacyn Pharmaceuticals cease offering these unapproved and misbranded drugs for sale to U.S. consumers and warned that failure to address violations may result in seizure, injunction, or other regulatory action.
Argus analysis
# FDA Warning Letter Analysis: Ketacyn Pharmaceuticals
**Company and Violations**
The FDA's Center for Drug Evaluation and Research issued a warning letter to Ketacyn Pharmaceuticals (www.ketacynpharma.com) on June 23, 2026, identifying the company as introducing unapproved and misbranded ketamine products into interstate commerce. The agency documented violations during a website review conducted February 26, 2026. Specific products cited include "Ketamine Solution for Injection (500 mg/10 mL)" marketed for intravenous and intramuscular use, and "Ketamine Gummies" promoted for mental clarity and mood enhancement. The FDA emphasized particular concern about injectable formulations, which bypass the body's natural defenses and carry serious risks including septicemia and sepsis.
**Regulatory Citations and Implications**
The warning identifies violations of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.). Section 505(a) requires FDA approval before new drugs enter commerce; neither product holds an approved application. Section 503(b)(1) classifies ketamine as a prescription drug due to its toxicity and requirement for practitioner supervision—meaning it cannot carry adequate directions for layperson use. Section 502(f)(1) requires adequate directions for safe use. These violations collectively establish that unapproved drugs lack the safety and efficacy assurances of FDA-reviewed products and may be contaminated, counterfeit, or contain varying ingredient amounts.
**Timeline and Industry Monitoring**
The warning letter directs immediate cessation of sales and allocates no specific compliance deadline beyond "promptly" and "without delay." The FDA explicitly warned that failure to address violations may result in seizure or injunction without further notice. Compliance officers in the nutritional supplement and emerging pharmaceutical sectors should monitor for enforcement actions against similar internet-based ketamine distributors, particularly those marketing to mental health or wellness audiences. The SPRAVATO REMS discussion signals FDA's heightened scrutiny of ketamine derivatives sold outside supervised medical settings.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Ketacyn Pharmaceuticals / www.ketacynpharma.com MARCS-CMS 725153 — June 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Ketacyn Pharmaceuticals / www.ketacynpharma.com United States info@ketacynpharma.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 23, 2026 WARNING LETTER Reference Number: MARCS-CMS 725153 To Ketacyn Pharmaceuticals: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.ketacynpharma.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.ketacynpharma.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS). 1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.ketacynpharma.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your website www.ketacynpharma.com, FDA Establishment Identifier (FEI) 3043544178, on February 26, 2026. Violations of the Federal Food, Dru…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was Ketacyn Pharmaceuticals / www.ketacynpharma.com cited for?
- The FDA Warning Letter to Ketacyn Pharmaceuticals / www.ketacynpharma.com (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs/Misbranded. Classification: Unapproved drug.
- When did FDA issue the warning letter to Ketacyn Pharmaceuticals / www.ketacynpharma.com?
- FDA issued the letter (MARCS-CMS 725153) on 2026-06-23 and posted it publicly on fda.gov on 2026-07-07.
- Is the FDA warning letter to Ketacyn Pharmaceuticals / www.ketacynpharma.com publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ketacyn-pharmaceuticals-wwwketacynpharmacom-725153-06232026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Ketacyn Pharmaceuticals / www.ketacynpharma.com in 2026-06-23 Warning Letter — Unapproved New Drugs/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-ketacyn-pharmaceuticals-www-ketacynpharma-com-2026-06-23-unapproved-drug
"FDA Cites Ketacyn Pharmaceuticals / www.ketacynpharma.com in 2026-06-23 Warning Letter — Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-ketacyn-pharmaceuticals-www-ketacynpharma-com-2026-06-23-unapproved-drug.
Argus HQ Research. "FDA Cites Ketacyn Pharmaceuticals / www.ketacynpharma.com in 2026-06-23 Warning Letter — Unapproved New Drugs/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-ketacyn-pharmaceuticals-www-ketacynpharma-com-2026-06-23-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_ketacyn_pharmaceuticals_www_ketacynpharma_com_2026_06_23_unapproved_drug_2026,
title = {FDA Cites Ketacyn Pharmaceuticals / www.ketacynpharma.com in 2026-06-23 Warning Letter — Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-ketacyn-pharmaceuticals-www-ketacynpharma-com-2026-06-23-unapproved-drug},
note = {Accessed: July 13, 2026}
}